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ABSTRACT: 
Ten metabolites of cyclosporine were isolated from the ethyl ether 
extract of bile from four liver transplant patients receiving cyclo-
sporine. Two of the metabolites were unique and previously uniden-
tified. Liquid-liquid partitioning into diethyl ether with subsequent 
defatting with n-hexane was used for the initial extraction from bile. 
Separation of the individual metabolites (A-J) was performed using 
a Sephadex LH-20 column and a gradient high performance liquid 
chromatographic method. The molecular weights of the isolated 
metabolites were determined by fast atom bombardment/mass 
spectrometry. Gas chromatography with mass spectrometric amino 
acid analysis was also used to identify the amino acid composition 
and the hydroxylation position of metabolites A, B, C, 0, and G. 
Proton nuclear magnetic resonance spectra were utilized to distin-
guish the chemical shifts of N-CH3 singlets and NH doublets of 
Cyclosporine (CsA)1 is a cyclic oligopeptide (fig. I) which is 
isolated from the fungus TO/.l'poc/adium i'!flarum Gams (I). The 
drug is used clinically as an immunosuppressant in organ trans-
plant patients (2) and for the treatment of autoimmune disorders 
(3). Cyclosporine is extensively metabolized in humans and in 
animals (4). Recent reports have demonstrated that several me-
tabolites of CsA have in vitro immunosuppressive activity (5). 
Results obtained by radioimmunoassay. which measures both 
parent drug and metabolites. in transplant patients over time 
indicate an association between high blood concentrations and 
nephrotoxicity (6). The metabolites of CsA mav therefore have 
both phannacologic and toxicologic propertie~ which warrant 
further investigation. 
Bile is the major pathway of CsA metabolites in humans and 
animals. Eleven metabolites isolated from human urine and 
animal bile. urine. and feces have been fully characterized chem-
ically (7). The tenninology used for the identified metabolites 
uses the number assigned by Maurer and Lemaire (7). with 
metabolite number 17 (M 17) being the primary ether-soluble 
cyciosporine metabolite. Metabolite 17 is hydroxylated in the 
number I amino acid position (fig. I), whereas metabolite I 
(M I) is hydroxylated at the number 9 amino acid. The other 
CsA metabolites which have been reported most commonly are 
a demethylated metabolite 21 (M21) and a cyclic ether metabo-
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metabolites A, B, C, and D. Metabolites A, E, F, H, I, llId " 
reported previously in human urine and animal bile. Me~ 
and 0 are dihydroxylated compounds which cannot be CItI!tw C 
scribed as previously isolated compounds. Metabolites B IIICI G .. 
novel metabolites with a mass fragment which corresllOndecl " 
loss of 131 Da from the protonated molecular ion (MW) In 1he:; 
atom bombardment/mass spectrometry, suggesting thlt tIIt--. 
bond in amino acid 1 has been modified. Metabolites B Inc! Q 
primarily isolated from the bile of one of the liver transpllnt ~ 
which contained abnormally high concentrations of these two ...... 
olites. The method described is an efficient procedure for 1--. 
milligram quantities of the major metabolites with greater .... '" 
purity. 
lite (M 18). Development of proper procedures for the isolabal 
ofCsA metabolites would be useful to obtain a sufficient amOUr 
of pure metabolites for standards for the quantitation of CiA 
metabolites and for phannacologic testing. 
Lensmeyer et af. (8) have recently rc;ported a method for • 
isolation of CsA metabolites from bile and tissues. Althoup 
significant quantities of the metabolites were found in bloc<. 
bile, and urine, no resolution of the closely eluting peaks of M I' 
MI. and M 18 was achieved using a cyano HPLC columt 
Christians and co-workers (9) also have reported a method ri 
CsA metabolite isolation from bile using two sequentiafOREFKm~ 
octyl columns. They reported seven structurally unidentified E~~ 
metabolite peaks, and were able to purify five of the compo~ 
for FAB/MS. The objective of this study was to develop a metho: 
of isolation of pure CsA metabolites from the bile of hI~ 
transplant patients and to identify the major metabolites in \he 
bile of this patient population. 
Materials and Methods 
Cyclosporine and trace amounts of purified metabolites M17. M 
M 18. and M21 were generously supplied by Dr. G. Maurer (Sandoz IDo: 
Basel. Switzerland). All organic solvents used in the procedure ~ 
liquid chromatographic grade (methanol and acetonitrile, J.T. Baker 
hexane. Fisher Scientific: ethyl ether. Burdick Jackson, Muskegon. MI. 
The water used was Type I reagent grade water produced by usi .. , 
Nanopure II, D3700 series canridge deionization system (Barnstead Co. 
Boston. MA). 
Isolation of CsA Metabolites. Bile was collected from the T-tubel d 
four adult patients who had undergone onhotopic liver transplantlliD& 
The bile was collected as untimed specimens, and the collectioo -
discontinued after at least 300 ml of bile was obtained from each pIIial 
For each patient's cumulative bile sample, one volume of fresh bile (pH 
= 7.5-8.2) was extracted in a separatory funnel with 1.5 volumes d 
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cliethyl ether and shaken gently for 2 mlO. and the ether was decanted. 
This procedure was repeated tWice more. and the ether fractions were 
combined and dned over anhydrous sodium sulfate. The ether extract 
.. evaporated to dryness under reduced pressure at 30T. The residue 
.. redissolved in 200 ml of methanol:water (90: 10). and defatted twice 
IlSiIll 200 ml of n-hexane. The defatted methanol·water solution was 
IIIen evaporated to dryness, The dned extract was dissolved in a minimal 
quantity of methanol and was applied to a Sephadex LH·20 column 
(Sipna). Elution with methanol was performed to obtain the clear major 
lllelabolite fractions. The metabolites were separated by using a gradient 
HPLC system. The gradient HPLC system consisted of a Waters 600 
"ulti-Solvent Delivery System (Waters Associates. Milford. MAl. The 
t'OIumn was an LC·18. 25·cm. 5-"m column (Supe\co. Bellefonte. PAl 
heated to 70"C. The UV detector was set at 214 nm (Lambda-Max Model 
4&1 LC Spectrophotometer. Waters Associates). The mobile phase con-
-.d of a linear gradient of acetonitrile and water as shown in table I. 
llIe eluates corresponding to the absorption peaks were collected into 
-sividual tubes. The eluate fraction was vortexed with an adequate 
..... me of ethyl ether to fully partition acetonitrile from the aqueous to ~~nic layer. The acetonitrile/ethyl ether mixture was evaporated to 
-111CSS under nitrogen gas at the ambient temperature. The remaining 
lQueous SOlution was lyophilized to obtain the dried metabolites. The 
~ty of the isolated metabolite fraction was tested by reinjection onto 
w~ HPLC column using the same HPLC conditions. The puritv of that 
III1&1e peak was defined as the percentage of area for that Peak (as 
I1Itqrated with a 3390A integrator, Hewlett·Packard. Avondale. PAl ~bv the total area for peaks resulting from injection of that fraction. 
... Spectrometric Analysis of CsA Metabolites. The structures of 
...:!:ted metabolites were investigated by using the mass spectrometry 
__ Is descnbed by Hartman and Jardine (10). Briefly. FAB/MS data 
COllected on a VG 12-350 quadruple mass spectrometer (VG 
l.J . TABLE I 
~r HPLC gradient profile used in the LC-IS, 25·cm coillmn/or 
___ C.l'c/osporine metabolite separation 
Acetonitrile: Water ____ Time Flow Rate 
-------------------------------------
""n ml/mm 
0.9 
0.9 
0.9 
0.9 
0.9 
43:57 
58:42 
73:27 
73:27 
43:57 
Masslab. Altrincham. United Kingdom!. The FAB/MS matrix solvent 
used was a 5: I mixture of dithiolhreitol:dllhlOerythritol heated to liquid 
at 90T and cooled to room temperature before use. The CsA metabolites 
(10 nmo\) were dissolved in 1.0 "I of aceto01trile and 0.5 "I of water and 
applied to the FAB/MS matrix. Data were acquired in the multichannel 
analyzer mode. scanning from m/: 1000-1500 at 10 sec/scan. The mass 
range was calibrated using CsA. Under these conditions, the CsA metab-
olites produced an intense protonated molecular ion (MH+). usually 
accompanied by a much less Intense fragment ion resulting from loss of 
the side chain of amino acid I (-113 Da for CsA itself). Such FAB/MS 
analysis allows determination of the overall metabolic transformations 
(hydroxylations. t • .ctemethylal1ons, etc.) that have occurred for each 
metabolite. 
To determine the specific transformation that has occurred with each 
amino acid type within the CsA molecule, an aliquot of each metabolite 
(50 "g) was totally hydrolyzed to the component amino acids by heating 
at 115·C in I ml of 6 N HCI for 48 hI' in evacuated glass tubes. The acid 
was then removed under vacuum down to 100 "I and then 3 ml of 
acetonitrile was added and the solution was blown dry under nitrogen at 
room temperature. The amino acids were converted to isobutyl esters 
using 3 N HCI in isobutyl alcohol at 120·C for 30 min. After drying 
under nitrogen at room temperature. acylation was carried out using 50 
"I of heptafluorobutyric anhydride and heating to 150·C for 10 min. 
After drying under nitrogen at room temperature. the resulting he pta· 
fluorobutyrated isobutyl esters of the metabolite amino acids were taken 
up in 25 "I of carbon disulfide and then analyzed by GC/MS. GC/MS 
was carried out on a Kratos MS50·DS55 mass spectrometer/computer 
system (Ramsey, NJ). fitted with a Carlo Erba 4160 gas chromatograph 
(Milan. Italy). The GC column was a Hewlett-Packard 190891 cross-
linked methyl silicone 25 m capillary column which was threaded 
through a heated GC/MS interface directly to the mass spectrometer 
electron ionization source that was operated at 70 eV. 
NMR Spectrometric Analysis of CsA Metabolites. The 'H NMR 
spectra of metabolites A. B. C. and D in CDC!, were determined at room 
temperature (22·0 by a Bruker/IBM AF·300 NMR Spectrometer (Bru· 
ker Instruments Inc .. Silberstreifen, Federal Republic of Germany). The 
90· pulse was 11.8 "sec and the chemical shift reference was trimethyl. 
silane as 0 ppm. -
Results 
The chromatogram of the separation of 10 CsA metabolites 
present in each of the four bile samples is depicted in fig. 2. A 
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total of 10 peaks were collected and analyzed from bile and were 
labeled A through J. The molecular weights and probable struc-
ture modifications of CsA are presented in table 2. Metabolites 
F. I. and J were obtained with greater than 95% purity in one 
HPLC separation. The purities of metabolites A. B. C. D. E. G. 
and H were higher than 90% in one HPLC separation. Metabo-
lites A. B. C. D. E. and H were reapplied to the HPLC column 
uSing the same procedure. and were further purified to greater 
than 95'0. Metabolite G was not purified further because of the 
small quantity obtained. Fig. 3 demonstrates the purity of me-
tabolites F (MI7). H (MI). I (MI8). and J (M21 1. 
!\Ietabolite Peak A. The protonated molecular ion of this 
metabolite was observed in the FAB/MS at ml: 1235 (MW) 
corresponding to an increase of 32 Da in comparison to the 
protonated molecular ion (ml: 1203 MH+) of CsA. A fragment 
at m/:: 1106 resulted from the loss of 129 Da from the protonated 
molecular ion, instead of 113 Da as observed for CsA. indicating 
that an additional oxygen was contained in amino acid I 
(MeBmt) of compound A. In the 'H NMR spectrum (300 MHz. 
CDC)'), the presence of seven N-CH, singlets and four NH 
doublets demonstrates that none of the methyl groups of the /1.'-
methylleucines was altered. GC/MS amino acid analysis indi-
cated that one of the N-methylleucine residues was hydroxylated 
at the 'Y-carbon. This metabolite was tentatively identified as M8 
according to the chromatographic scheme of Maurer el al. (4). 
Metabolite Peak B. The F AB/MS of metabolite B indicated a 
molecular ion species at ml: 1237 (MH+) corresponding to an 
increase of 34 Da over CsA. The fragment at ml: 1106 resulting 
from the loss of 131 Da from the protonated molecular ion 
indicates that the additional oxygen and 2H were contained in 
amino acid I of compound B. The addition of 2H suggests that 
the double bond in amino acid I is saturated. The 'H NMR 
spectrum showed the signals of four NH doublets and seven N-
CH , singlets. indicating that A'-demethylation has not occurred. 
GC/MS amino acid analvsis revealed that one of the N-methvl-
leucine groups had bee~ hydroxylated on the 'Y-carbon. By 
comparison with the identified II cyclosporine metabolites. the 
loss of 131 Da from the MH+ suggests that metabolite B could 
be a new metabolite with a novel modification on the double 
bond of amino acid I. This metabolite is a dihydroxyl + 2H 
derivative of CsA. 
Metabolite Peak C. The protonated molecular ion at ml: 
W ACM8) () 
Z 
~ 
III 
II: 
0 
1235 (MW) was consistent with the addition of 
atoms. One of the N-methylleucines was hydroxylateci 
carbon. as demonstrated in the GC/MS amino acid 
'H NMR spectrum showed seven N-CH, singlets and i~ 
that no N-demethylation had ?"curred, The patte.ll. of c~ 
shifts of these seven N-CH, smglets In NMR was different ~ 
metabolite D. A fragment from the loss of a C7 . fragment., 
amino acid I was not observed In the FAB/MS. ThiS metabot..r 
could be a dihydroxyl derivative of CsA. 
Metabolite Peak D. The protonated molecular ion Was II 
:: 1235 (MW) which is an addition of 32 Da. to CSA. ~ 
fragment ion at ml: 1106 mdlcates that an ~ddltllnal l~~ 
was contained in the C7 fragm:n~ ofamlno aCid I for metaboinr 
D. GC/MS amino acid analYSIS indicated one of the N-meth ~ 
leucine moieties was hydroxylated on its 1'-carbon. The IH k~k 
spectrum showed the presence of seven N-CHJ singlet and r_ 
NH doublet peaks. which indicate~ that no k~emethvlalioa 
had occurred. ThiS metabohte IS a dlhydroxyl den~al1ve of~ 
Metabolite Peak E. The protonated molecular Ion Was at "'; 
: 1205 (MW), which is an addition of 2 Da over CsA. This . 
considered to be the addition of one oxygen (+ 16 Da) and u: 
loss of one methyl group (-14 Da). The fragment OCCurred It 
ml: 1092. or a loss from MW of 113 Da, which indicated that 
no hydroxylation occurred on the side chain of amino acid I 
This metabolite was tentatively identified as M 13 accordina 10 
the chromatographic scheme of Maurer et al. (4), 
Metabolite Peak F. The protonated molecular ion was at "" 
: 1219 (MW). which is an addition of 16 Da relative to CIA. 
The fragment at ml: 1090 indicated that the additional oxYin 
was contained in the C7 fragment of amino acid 1. This metab-
olite exhibited the identical HPLC chromatographic retentiOll 
time as authentic M 17 obtained from Maurer. This metabolitt 
was thus identified as M 17. 
Metabolite Peak G. The protonated molecular ion peak was 
at ml: 1221 (MH+). which is an addition of 18 Da relative 10 
CsA. The fragment at ml: 1090 indicated that the additiOnal 
oxygen and 2H were contained in the C7 fragment of amino 
acid I. The loss of 131 Da was similar to the C7 fragment loa 
from metabolite B. Thus. metabolite G could be a previously 
unidentified CsA metabolite with a novel modification in amino 
acid I similar to that observed in metabolite B. This metabolitt 
is a monohydroxyl + 2H derivative of CsA. 
FCMI7) 
~ [IMI3) III ICMI81 ~ G 
C 
o 15 30 45 60 75 90 K>5 120 
RETENTION TIME (min) 
FIG. 2. HPLC cllromalO!(ram (}(I1ll' separation o( 10 metaholites o(CsAfrom the ether extract o/the hill' ora /i"er transplant patient. 
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TABLE ~ 
Profll'rI/('S "ffK~E}/a/fDd mewho/I/I'S or C.I.·/ 
Obsened 
Metabolite Motecular HO·McBmt" HO-S-MeLeu CsA lkriv31ive 
WeIgh I 
A(M8) 1134 Y Y Dihydroxyl 
B 1~PS Y Y Dihydroxyl + 
~e 
C I ~KD4 Y Dihydroxyl 
D 1134 Y Y Dihydroxyl 
E(MI3) 110-1 Monohydroxyl-
demethyl 
F(MI?) 121 ~ Y ;\ Monohydroxyl 
G 1120 Y :\ Monohydroxyl 
+ 2H 
H(MI) 121X ;\ Y Monohydroxyl 
I(MI8) 1O1~ Y ;\ Monoh\droxyl 
J IM21) II i<~ '\ '.; .\'-Dcmcthyl 
(sA 1OEF~ '\ '\ 
• MeBmt. (4R )-4-[( il-:!-huten~ 1]-4 .. \·dlmcthyl-l.-threonmc lamino 
ICld I ofCsA): .\'-MeLeu. S-mclhylleucme. 
Metabolite Peak H. The protonated molecular ion at m/: 
1219 indicated thaI an additional oxygen molecule was attached 
10 this metabolite. The fragment ion at 111/: 1106 indicated that 
the oxygen was not attached to the C7 fragment of amino acid 
I. The HPLC retention time of this metabolite was same as 
authentic M I obtained from Maurer. Thus, metabolite H is 
considered to be M I. 
Metabolite Peak I. The protonated molecular ion peak of this 
IDCtabolite was at m/= 1219 (MW) and again had one additional 
oxygen relative to CsA. The fragment ion at 111/: 1090 indicated 
lhat the additional oxygen atom was attached to the C7 fragment 
0{ amino acid I, The HPLC retention time of metabolite I was 
die same as authentic M 18 from Maurer. and this metabolite 
-. therefore. identified as M 18. 
Metabolite Peak J. The metabolite J produced a protonated 
IklIccular ion at m/= 1189 (MW) or 14 Da less than CsA, The 
hautent ion at m/= 1076 indicated that no hydroxylation had 
ClCturred on amino acid I, The HPLC retention of this metabolite 
-as the same as authentic M21 obtained from Maurer. This 
lletabolite was assigned as M21. 
Discussion 
Ten metabolites of CsA have been isolated from the ether 
~fract of bile of liver transplant patients receiving CsA therapy. 
. method described is an efficient procedure for obtaining 
:::am quantities of CsA metabolites for structural character-
. . and to perform in l'ilro activity tests. By making 36 
:::ons from approximately 300 ml of bile onto the HPLC 
ts, n (see fig, 2), 1.4 mg of M 17 with a purity of greater than 
. '-'as Obtained. The metabolite content of bile varies among ~lsK The bile used in this isolation was chosen because of its 
t of new metabolites Band G. ~ugh none of the compounds isolated by Christians and 
~ers (9) appear to be similar to the Band G metabolites 
~ herein. the two peaks which they found difficult to 
~ ~ likely to represent our recently reported aldehydic 
... M lites ( II). Metabolites F. H, I. J were identified as M 17. 
~1UI M21. respectively. as assigned by Maurer and co-
lilt, .(4), Metabolites A and E are also most likely M8 and 
. "Identified by Maurer. The presence of two new metabo-
G), which have not been reported previously. suggests 
MI7(F') 
o 15 30 60 90 105 
M,(H) 
K~ 
_-JlL...-----
o 15 30 45 60 90 105 
o 15 30 45 60 75 90 105 
'" M21(J) ~ ~ III § L = JL 
0 15 30 45 60 75 90 105 
TIME (min) 
FIG. 3. flPLC chrvmalOgrams oFrill' {,w/a/I'd c.I'c/osporinc metaholll£', 
F (M17). II (JI1), I (JI181. and J (.\/111 on an LC-IS 15-cm cO/limn. 
that CsA metabolism in liver transplant patients could be differ-
ent from previous animal models or normal human subjects. 
These IO CsA metabolites can be detected in varying concentra-
tions in each of the four bile collections from liver transplant 
patients. Twenty-five other peaks present in the chromatogram 
of fig. 2 could be additional CsA metabolites but were not 
investigated. The full assignments of the positions of structural 
modifications of metabolites A. B, C, D. E. and G cannot be 
achieved. as it was not possible to obtain a sufficient quantity of 
metabolite to perform a DC NMR spectrum at this time. 
The relative concentrations of new metabolites Band G were 
particularly high in the bile of one of the liver transplant patients 
with impaired liver function. The pharmacologic/toxicologic 
activities of these new metabolites will be investigated when 
sufficient quantities of these compounds can be obtained. We 
have observed unusually large peaks with identical retention 
times of Metabolites Band G in the blood of liver (12). heart. 
and bone marrow transplant patients using a similar chromatog-
raphy system. Liver dysfunction occurs frequently in these pa-
296 WANG ET AL. 
tient population~K and mav contribute to the formation of the 
new mctaholites. -
Pure metaholite\ F (M 17). H (M I). and J (M:!]) obtained by 
using thi\ method h~ \e been tested for in rifro immunosuppres-
sive activity on l-hmphoc)1e cultures. These results have shown 
metaholite I· to have substantial immunosuppressive activity 
against hlOp<;y-grown lymphoc~1es and to have synergistic inhib-
Itory effect with ("\;\ on lymphocyte proliferation (13. 14). Ethyl 
acetate extrat'lIon of the bile after ethyl ether extraction produces 
small amounts of metabolites A through E and several more 
unidentified polar peaks in the chromatogram of the same HPLC 
system. The major polar metabolite of CsA is the carboxylated 
metabolite (15). However. none of the polar CsA metabolites 
appears to have in vitro immunosuppressive activity (16). 
In addition to immunosuppressive activity of the metabolites. 
recent reports suggest that CsA metabolites are associated with 
CsA nephrotoxicitv (6). Further studies of the pharmacologic/ 
toxicologic importance of the CsA metabolites in transplant 
patients is critical for a complete understanding of the action of 
cyclosporinc and differences in response among transplant pop-
ulations. 
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